Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA and Pembrolizumab in Solid Tumors
NCT02717156Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Nov 2016
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sephb4-hsa in urothelial carcinoma (UC), prostate cancer (PCa), sponsored by University of Southern California. Started Nov 2016; status: active, not recruiting.
02
Drugs
sephb4-hsa
03
Conditions
urothelial carcinoma (UC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02717156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717156.